Piramal Pharma Limited (PPL) has achieved a score of 63 in the 2025 S&P Global Corporate Sustainability Assessment (CSA), marking a significant 15% increase from the previous year’s score of 55. This improvement positions the company in the 91st percentile within the pharmaceutical industry, reflecting its ongoing commitment to sustainability and responsible business practices.
The S&P Global CSA is a highly regarded annual evaluation that assesses the sustainability performance of thousands of companies across various sectors. It uses criteria such as environmental, social, and governance (ESG) performance, governance maturity, and long-term value creation to gauge a company’s commitment to sustainability. With its comprehensive benchmarking framework, the CSA serves as a critical tool for organizations to compare their performance against peers and identify potential risks and opportunities.
PPL’s notable increase in score demonstrates its dedication to enhancing sustainable practices. The company’s approach is built on four key pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. By focusing on these areas, PPL strives to ensure compliance and responsible operations that benefit its partners, patients, and the environment.
“Our progress on the S&P Global CSA underscores our unwavering dedication to responsible operations and sustainable growth,” stated Peter DeYoung, CEO of Piramal Global Pharma. “As we continue to expand, we remain committed to excellence in every aspect of our work, ensuring our efforts contribute to a healthier future for all.”
PPL is leveraging the insights gained from the CSA to further enhance its sustainability initiatives. The company aims to aid its partners in driving positive change, reflecting a broader commitment to corporate responsibility.
Piramal Pharma Limited operates a diverse portfolio of products and services through its 17 global development and manufacturing facilities, serving markets in over 100 countries. The company includes Piramal Pharma Solutions, a leading contract development and manufacturing organization (CDMO), and Piramal Critical Care, which specializes in complex hospital generics. Additionally, PPL has a strategic minority investment in Yapan Bio Private Limited, a company focused on biologics and vaccine segments.
PPL’s ongoing efforts to improve sustainability practices demonstrate its commitment to being a responsible corporate citizen in the global pharmaceutical landscape. As the company continues to advance its initiatives, it is poised to make a significant impact in promoting sustainable growth and development within the industry.
